Dishman Carbogen Amcis Ltd (DCAL) Q4FY26 Management Mirror - Mar-2026 Qtr
Revenue Growth
Management targets a 15% consolidated revenue CAGR over the next three years (Mar'26 Qtr), shifting focus from the specific FY26 8% to 10% growth target discussed in the Sep'25 Qtr. The revenue mix is expected to stabilize at 85% from the CDMO segment and 15% from marketable molecules over the coming years. [Status: Initiated]
4 more themes on the ELITE plan.